During 2017 and 2018, the FDA put life aplenty into the AML space by taking action to clear or reapprove no fewer than eight drugs for acute myeloid leukemia (AML), including Agios Pharmaceuticals Inc.'s Tibsovo (ivosidenib) to treat relapsed or refractory disease with an isocitrate dehydrogenase 1 (IDH1) mutation who are not eligible for standard therapy and Idhifa (enasidenib), cleared for patients with IDH2 mutations. And the indication only looks to grow hotter.